

REMARKS

Claims 1-53 are presented in this application. In this amendment, claims 1-28 have been cancelled. In lieu thereof, the application contains newly added claims 29-53 which are based on the originally filed claims and the specification at page 14, lines 28-31. Newly added claims have been written to place them in form appropriate to US practice, to remove multiple dependencies for the purpose of reducing fees, and/or to rectify obvious typographical errors.


Applicants have amended the specification for purposes of adding the priority information. The title was amended to correct obvious typographical errors. Further, appropriate headings have been inserted on accordance to 37 CFR 1.77. Applicants have attached an Abstract on a separate sheet of paper as required by US practice.

Entry of the amendment prior to the examination of the application and calculation of the filing fee is respectfully requested.

It is respectfully submitted that the present application is in condition for allowance. An early consideration and Notice of Allowance are earnestly solicited.

The Commissioner is hereby authorized in this, concurrent, and future replies, to charge any fees or credit any overpayment, particularly including any fees required under 37 CFR Sect 1.16 or 1.17, and any necessary extension of time fees, to deposit Account No. 07-1392.

Respectfully submitted,


Bonnie L. Deppenbrock
Attorney for Applicant
Registration No. 28,209

Date: 16 June 2005
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709-3398
Phone: 919-483-1577
Facsimile: 919-483-7988